Full-spectrum CBD capsules: dosage and the French framework

A soft capsule, or softgel, is a sealed gelatine shell containing an oily suspension of CBD. Unlike the hard capsule made of two interlocking half-cylinders, it delivers a more consistent dose from one capsule to the next. Common dosages ranged from 10 to 50 mg of CBD per capsule, with 25 mg the most widespread format. The bioavailability of this oral route nevertheless remains lower than that of the sublingual route, because of first-pass liver metabolism: our guide to how CBD oil is made sets out that mechanism in detail.

The market distinguishes three categories of formulation. Full spectrum contains all the compounds of hemp, including traces of THC within the legal limit of 0.30%, as well as minor cannabinoids such as CBG or CBN. Broad spectrum keeps those minor compounds but removes the THC by filtration. The isolate, lastly, contains only pure CBD at 99%. The hypothesis of a superior "entourage effect" from full spectrum remains scientifically debated: no European authority has validated any superiority in efficacy of one formulation over another.

Two decisions tipped the capsule market this year. On 9 February 2026, the EFSA published a provisionally safe daily dose of 0.0275 mg of CBD per kilogram of body weight, that is around 2 mg per day for a 70 kg adult, a threshold far below the 25 or 50 mg of a typical capsule. Then, since 15 May 2026, the DGAL has strictly applied the Novel Food regulation (EU 2015/2283): CBD capsules without European authorisation are withdrawn from compliant distribution channels.

The framework of THC at or below 0.30% in the finished product, laid down by the Conseil d'État decision of 29 December 2022, continues to apply to non-food products: oils for cosmetic use, flowers, resins, e-liquids. Ingested capsules, for their part, have fallen outside that framework since May 2026, save for a specific Novel Food authorisation that no manufacturer has yet obtained to date.

No brand can state that a CBD capsule "reduces stress" or "promotes sleep". Such wording amounts to health claims, which are not authorised by the EFSA under regulation EC no. 1924/2006. Inspections by the DGCCRF regularly cover this point, as well as labelling and the presence of prohibited cannabinoids such as HHC or THCP.

CBD is metabolised by the liver enzymes CYP3A4 and CYP2C19, which can interfere with many medicines: anticoagulants, antiepileptics, immunosuppressants. Pharmaceutical advice is recommended before any regular use. It is not advised for pregnant or breastfeeding women, minors, or people on medical treatment. Always insist on an independent certificate of analysis confirming the CBD content, the THC level and the absence of synthetic cannabinoids prohibited since 2023-2024.

CBD is not a medicine. If you are in any doubt about a drug interaction, consult your pharmacist or your doctor.

Are CBD capsules still on sale in France?

Since 15 May 2026, the DGAL has been withdrawing CBD food products that lack Novel Food authorisation. Some brands are reformulating as cosmetics for external use; others have stopped selling their ingested ranges.

What is the difference between full spectrum and isolate?

Full spectrum keeps all the compounds of hemp, including traces of THC. The isolate contains only pure CBD. No European agency has validated any superiority in efficacy of one over the other.

What daily dose is considered safe?

In February 2026 the EFSA published a provisionally safe dose of 0.0275 mg/kg/day, that is around 2 mg per day for a 70 kg adult, a threshold far below the usual dosages of commercial capsules.

Capsule or sublingual oil: what difference in absorption?

The capsule passes through the digestive system and undergoes first-pass liver metabolism, which reduces its bioavailability. Oil held under the tongue is absorbed faster and more efficiently.